BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Saharsh Davuluri takes over as CEO & MD of Neuland to lead CDMO expansion

01 April 2026 | News

Davuluri has been with the company for more than 18 years

Hyderabad-based Neuland Laboratories [NLL], a global contract development and manufacturing organization (CDMO) specialising in complex APIs, has announced a leadership change. Saharsh Davuluri will assume the role of Chief Executive Officer (CEO) and Managing Director (MD), effective immediately, as the company moves into its next stage of CDMO growth.

Davuluri has been with the company for more than 18 years and will position the CDMO as a premier global API process development and commercial manufacturing specialist. Neuland's recent successes have been built on a growing reputation for scale-up of complex APIs and peptides, and the business has tripled its contract services revenues during the last 3-years.

Davuluri has led Neuland's transformation into a new chemical entity (NCE)-focused drug substance CDMO. In recent years, the company has secured a growing number of commercial manufacturing contracts with global innovator companies, reflecting rising demand for its strengths in process chemistry, scale-up, and reliable commercial supply. Davuluri succeeds Sucheth Davuluri, who has played a key role in the company's transformation towards a CDMOâ??focused business model and will now assume the role of Executive Vice Chairman of the Company.

Neuland is embarking on an aggressive expansion phase and could, pending customer approvals, secure several more commercial NCE contracts [including peptides] over the next one to two years.

The CDMO operates three US FDA-inspected manufacturing facilities and a 40,000 sq. ft. R&D facility, with 1218 KL of installed capacity and more than 20 commercial contracts across APIs and intermediates. The company's recent growth has been supported by its ability to accelerate development timelines through parallel development strategies, while maintaining a strong regulatory track record across 18 US FDA inspections.